FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Proper Pharmacovigilance needed. The U.S. Food and Drug Administration (FDA) is warning that the type 2 Diabetes medicines Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin may cause joint pain that can be severe and disabling.
FDA has added a new warning and precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. Patients should not stop taking their DPP-4 inhibitor medicine, but should contact their health care professional right away if they experience severe and persistent joint pain. Health care professionals should consider DPP-4 inhibitors as a possible cause of severe joint pain and discontinue the drug if appropriate. DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 Diabetes.…
